Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

Summary

The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.

Timeline

Start

2019-08-26

Primary completion

2021-08-11

Completion

2024-04-30

Publications

• Yu S, Kim BK, Wang H, Zhou J, Banerjee P, Lincy J, Reshetnyak E, Li Z, Leclair D, Wang SJ. Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study. J Headache Pain. 2026 Jun 17. doi: 10.1186/s10194-026-02406-y. Online ahead of print.
• Yu S, Kim BK, Wang H, Zhou J, Wan Q, Yu T, Lian Y, Arkuszewski M, Ecochard L, Wen S, Yin F, Li Z, Su W, Wang SJ. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain. 2022 Nov 21;23(1):146. doi: 10.1186/s10194-022-01514-9.

Drugs

Indications